sales@reportocean.com (Bussiness Sales)
+18882123539 (Us - Toll Free)
+919997112116 (Rest Of World)
Global Antibody Therapeutics Market Size study, by Format, by Route of Administration, by Source, by Disease Areas, by End User and Regional Forecasts 2024-2032

Global Antibody Therapeutics Market Size study, by Format, by Route...

Home / Categories / Healthcare
Global Antibody Therapeutics Market Size study, by Format, by Route of Administration, by Source, by Disease Areas, by End User and Regional Forecasts 2024-2032
Global Antibody Therapeutics Market Size...
Report Code
RO1/103/2901

Publish Date
30/Aug/2024

Pages
200
PRICE
$ 1800/-
This is a single user license, allowing one specific user access to the product. The product is a PDF.
$ 2350/-
This is a 1-5 user license, allowing up to five users have access to the product. The product is a PDF.
$ 2850/-
This is an enterprise license, allowing all employees within your organization access to the product. The product is a PDF..
The Global Antibody Therapeutics Market is valued approximately at USD 248.79 billion in 2023 and is anticipated to grow with a healthy growth rate of more than 14.89% over the forecast period 2024-2032. Antibody therapeutics represent a class of medical treatments leveraging antibodies to enhance or mimic the immune system's ability to combat diseases. With their high specificity and lower toxicity compared to conventional drugs, antibody therapeutics have emerged as effective treatments for a plethora of conditions, including cancers, autoimmune diseases, and infectious diseases. The growing prevalence of chronic diseases and increasing healthcare expenditure globally have significantly driven the adoption of antibody therapeutics. Despite these challenges, advancements in medical technology are leading to more efficient antibody production, and the emergence of next-generation antibodies along with supportive government initiatives for cancer care are anticipated to provide substantial opportunities for market growth.

The market dynamics are shaped by the significant utilization of monoclonal antibodies due to numerous regulatory approvals, and the growing use of antibody fragments for better tumour penetration and reduced immunogenicity. Bispecific antibodies, with their dual affinity, are also gaining traction for their diverse applications in cancer therapy. Furthermore, the intravenous route remains a common method for delivering antibody therapeutics, ensuring immediate bioavailability and rapid therapeutic action, whereas subcutaneous administration offers the convenience of self-administration and cost-effectiveness. However, the market faces challenges such as high development costs and complex regulatory approval processes, these factors anticipated to restrain market growth between 2024 and 2032.

Geographically, the market analysis covers key regions including North America, Europe, Asia Pacific, Latin America, and the Rest of the World. The North America leads the market driven by a well-established R&D ecosystem and high healthcare expenditure. North America, particularly the United States, boasts a highly advanced healthcare system with a strong focus on research and development. This infrastructure supports extensive clinical trials and facilitates the rapid adoption of new therapies. Various leading pharmaceutical and biotechnology companies, such as Amgen, Genentech (a subsidiary of Roche), and Johnson & Johnson, are based in North America. These companies invest heavily in the development and commercialization of antibody therapeutics. Furthermore, the Asia Pacific region is also anticipated to witness the fastest growth, driven by growing healthcare infrastructure and increased incidence of chronic diseases. Moreover, the European Union also plays a pivotal role in the antibody therapeutics landscape, with strong pharmaceutical industries and comprehensive intellectual property rights frameworks.

Major market players included in this report are:
AbbVie Inc.
AbCellera Biologics Inc.
Adaptimmune Therapeutics PLC
ADC Therapeutics SA
Aenova Holding GmbH
Almac Group Limited
Amgen Inc.
Antikor Biopharma
Argenx SE
Astellas Pharma Inc.
AstraZeneca PLC
Baxter International Inc.
Bayer AG
Becton, Dickinson and Company
Bio-Rad Laboratories, Inc.
The detailed segments and sub-segment of the market are explained below:
By Format:
Antibody Fragment
Bispecific Antibody
Monoclonal Antibody
Polyclonal Antibody
By Route of Administration:
Intravenous
Subcutaneous
By Source:
Chimeric
Human
Humanized
By Disease Areas:
Autoimmune & Inflammatory Diseases
Hematology
Immunology
Neurology
Oncology
Osteology
By End User:
Hospitals
Long-term Care Facilities
By Region:
North America:
U.S.
Canada
Europe:
UK
Germany
France
Spain
Italy
ROE
Asia Pacific:
China
India
Japan
Australia
South Korea
RoAPAC
Latin America:
Brazil
Mexico
Middle East & Africa:
Saudi Arabia
South Africa
RoMEA
Years considered for the study are as follows:
Historical year - 2022
Base year - 2023
Forecast period - 2024 to 2032
Key Takeaways:
Market Estimates & Forecast for 10 years from 2022 to 2032.
Annualized revenues and regional level analysis for each market segment.
Detailed analysis of geographical landscape with Country level analysis of major regions.
Competitive landscape with information on major players in the market.
Analysis of key business strategies and recommendations on future market approach.
Analysis of competitive structure of the market.
Demand side and supply side analysis of the market.

OUR CLIENTS

500 N Michigan Ave, Suite 600, Chicago, Illinois 60611, UNITED STATES
+18882123539
sales@reportocean.com